# Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients

> **NCT01347983** · PHASE3 · COMPLETED · sponsor: **Chugai Pharma Taiwan** · enrollment: 72 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Tocilizumab+Methotrexate(MTX)

## Key facts

- **NCT ID:** NCT01347983
- **Lead sponsor:** Chugai Pharma Taiwan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2013-03
- **Final completion:** 2013-04
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2013-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01347983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01347983, "Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01347983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*